micro-community-banner
Profile Image
  • Add Media
  • Saved

2yr
The SGLT2 Inhibitor Empagliflozin Attenuates Atherosclerosis Progression by Inducing Autophagy

The SGLT2 Inhibitor Empagliflozin Attenuates Atherosclerosis Progression by Inducing Autophagy

Source : https://link.springer.com/article/10.1007/s13105-023-00974-0

Cardiovascular disease due to atherosclerosis is one of the leading causes of death worldwide; however, the underlying mechanism has yet to be defined. The sodium-dependent glucose transporter 2 inhibitor (SGLT2i)...

Empagliflozin activates autophagy through the AMPK signaling pathway to delay the evolution of atherosclerosis, indicating that it may represent a new and effective drug for the clinical treatment of atherosclerosis.

Profile Image
  • Saved

2yr

SGLT2 Inhibitors for Patients With Heart Failure With Preserved Ejection Fraction in China: a Cost-Effectiveness Study

Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.1155210/full

Background: The potential benefits of intervention with empagliflozin or dapagliflozin for patients with heart failure with preserved ejection fraction (HFpEF) were first demonstrated in the EMPEROR-Preserved and DELIVER studies.

In Chinese healthcare, the interventions (empagliflozin or dapagliflozin) for HFpEF were more cost-effective than the comparators. Our study has provided a quantitative evaluation of the costs and benefits of such interventions for a lifetime using the model.

Profile Image
  • Saved

2yr
Empagliflozin Improves Circulating Vascular Regenerative Cell Content in People Not Living With Diabetes But With Cardiovascular Risk Factors

Empagliflozin Improves Circulating Vascular Regenerative Cell Content in People Not Living With Diabetes But With Cardiovascular Risk Factors

Source : https://pubmed.ncbi.nlm.nih.gov/37773589/

SGLT2 inhibitors have been reported to reduce cardiovascular events and heart failure in people with and without diabetes. These medications have been shown to counter regenerative cell exhaustion in the...

Empagliflozin promoted the recovery of multiple circulating pro-vascular cell subsets in people without diabetes suggesting that the cardiovascular benefits of SGLT2 inhibitors may be attributed in part to the attenuation of vascular regenerative cell exhaustion that is independent of diabetes status.

Profile Image
  • Saved

2yr

What is the exact mechanism which results in the clinical outcomes, and Heart Failure patients with SGPT2 inhibitors?

Profile Image
  • Saved

2yr
Preview of the 2023 Heart Failure Society of America Annual Scientific Meeting

The Heart Failure Society of America (HFSA) is hosting its Annual Scientific Meeting (ASM) at the Huntington Convention Center in Cleveland from Oct. 6 to 9, 2023.

The vision of HFSA is to reduce the burden of heart failure and provide a platform for collaboration, education, innovation, research, and advocacy to improve care in this area. The HFSA ASM is where heart failure teams gather for sessions on heart failure science, research, practical management, and networking opportunities. 

We will be covering the event for you, so check your email for highlights and a wrap-up of the conference. Click above for an exclusive preview of the event.